Eli Lilly (LLY) shares surged Tuesday morning, after the company reported strong fourth-quarter results driven by high demand for weight loss drug Zepbound and diabetes treatment Mounjaro. Evan Seigerman, BMO Capital Markets Managing Director joins Yahoo Finance Live, saying he continues to be "surprised at the demand" for these drugs.
Seigerman says Eli Lilly is "the leader in the obesity and diabetes space," driving a higher 2024 multiple on "sustained growth." He notes tracking shows "tens of billions" in potential sales this year for Zepbound and Mounjaro alone.
Given the "supply market," Seigerman says every bottle made likely sells due to intense demand. So Lilly doesn't need "a ton of marketing" now, however manufacturing capacity and market access are "critical." He notes getting employers to cover costs will be key, as most users currently pay out-of-pocket. He also emphasizes investing in manufacturing to ensure it can meet the outstanding demand.
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance..Eli Lilly weight loss drugs are 'mega-growth assets' BMO's Evan Seigerman says e604422bf